Skip to content

Disc Medicine IRON Earnings yield

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-1.7%-3.6pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-21.3%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-16.9%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-4.2%-1.9pp

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on trailing twelve months.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's earnings yield?
Disc Medicine (IRON) reported earnings yield of -9.9% in Q1 2026.
How has Disc Medicine's earnings yield changed year-over-year?
Disc Medicine's earnings yield decreased by 45.9% year-over-year, from -6.8% to -9.9%.
What is the long-term trend for Disc Medicine's earnings yield?
Over 4 years (2020 to 2025), Disc Medicine's earnings yield has grown at a -11.6% compound annual growth rate (CAGR), from -11.6% to -7.1%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.